Financial Comparison: Taysha Gene Therapies (NASDAQ:TSHA) and Amylyx Pharmaceuticals (NASDAQ:AMLX)

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Taysha Gene Therapies (NASDAQ:TSHA) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, risk, profitability, analyst recommendations and dividends.

Earnings and Valuation

This table compares Amylyx Pharmaceuticals and Taysha Gene Therapies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37 million	37.11	-$144.74 million	($1.43)	-20.35
Taysha Gene Therapies	$9.77 million	162.41	-$109.00 million	($0.42)	-11.60

Taysha Gene Therapies has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Amylyx Pharmaceuticals and Taysha Gene Therapies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1	0	7	2	3.00
Taysha Gene Therapies	1	0	12	2	3.00

Amylyx Pharmaceuticals currently has a consensus price target of $38.86, indicating a potential upside of 33.53%. Taysha Gene Therapies has a consensus price target of $12.77, indicating a potential upside of 162.20%. Given Taysha Gene Therapies’ higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Amylyx Pharmaceuticals.

Profitability

This table compares Amylyx Pharmaceuticals and Taysha Gene Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

Institutional and Insider Ownership

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Amylyx Pharmaceuticals has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

Summary

Taysha Gene Therapies beats Amylyx Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.